Review Article

Efficacy of Moxibustion for Primary Osteoporosis: A Trial Sequential Meta-Analysis of Randomized Controlled Trials

Xiang Li, Zihan Yin, Xiao Li, Bingzun Yin, Yixiang Liu, Wenchuan Qi, and Fanrong Liang

1School of Acu-Mox and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China
2Luohu Hospital of Traditional Chinese Medicine, Shenzhen, China

Correspondence should be addressed to Wenchuan Qi; qiwenchuan@cdutcm.edu.cn and Fanrong Liang; acuresearch@126.com

Received 1 March 2022; Revised 21 July 2022; Accepted 12 August 2022; Published 27 September 2022

Academic Editor: Woon-Man Kung

Copyright © 2022 Xiang Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Primary osteoporosis (PO) is a systemic metabolic skeletal disease. Previous studies have shown that moxibustion can reduce pain intensity and enhance response rate, bone mineral density (BMD), and living function of the patients with PO. However, consensus on its efficacy does not exist, and evidence of moxibustion for PO is also insufficient.

Methods. We searched five English and four Chinese databases with various additional sources and published reviews through December 1, 2021, to evaluate potentially concerned randomized controlled trials (RCTs). Two independent researchers addressed selection screening, data extraction, and risk of bias assessment. The data of this meta-analysis were analyzed using the RevMan v.5.4 software. Additionally, the trial sequential analysis v.0.9.5.10β was used to estimate the sample size. In contrast, the quality of evidence from the RCTs was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation tool.

Results. The current meta-analysis included 14 RCTs containing 898 participants. The methodological quality of the RCTs was moderate. The review demonstrated that a combination of moxibustion and conventional medicine (CM) significantly reduced pain intensity and improved the BMD compared with CM. Furthermore, it was found that moxibustion plus CM/moxibustion could improve response rates compared with CM. However, it was found that the reduction of pain intensity and improvement of BMD by moxibustion showed no significant difference compared with CM. It was also evident that the sample size of most outcomes was inadequate. Moreover, all evidence obtained in this study was ranked as low to critically low. Conclusions. In conclusion, it was demonstrated that moxibustion is a potentially effective agent for treating PO. However, high-quality studies should be implemented in the future because this study only obtained low-quality evidence. This study was registered in the PROSPERO platform (CRD42021291310).

1. Introduction

Primary osteoporosis (PO) is a systemic metabolic skeletal disease that is characterized by reduced bone mineral density (BMD) and microarchitectural [1, 2]. Additionally, PO may cause significant harm, including chronic pain and fragility fractures, which lead to decreased quality of life [1, 2]. PO has become one of the most frequent human diseases and a primary global public health issue with the progressive aging of the population [3]. In 2010, it was reported that the number of adults with osteoporosis was 10.2 million, affecting between 6 and 11% of adults aged 50 years and above, translating to approximately one in every 9–17 adults [4, 5]. Furthermore, the annual total population of facility-related hospitals in the United States costs $5.1 billion [6, 7]. Conversely, the Seventh National Census statistics indicated that the prevalence of PO among Chinese senior citizens over 60 years was approximately 36% [8], with nearly 95 million cases of PO in China. Therefore, because of the growing number of senior citizens worldwide, the management of PO has gained increased attention in many nations [9, 10].

The United States Food and Drug Administration (FDA) has approved multiple pharmacotherapy therapies to treat...
Evidence-Based Complementary and Alternative Medicine

PO [11]. However, pharmacotherapy has definite limitations in numerous clinical practices [12, 13]. Therefore, there is an urgent need to investigate a new effective non-pharmacological therapy for PO. Moxibustion is a non-pharmacological therapy widely used to manage osteoporosis in China [14–16]. Some previous studies have revealed that moxibustion may alleviate osteoporosis pain, improve BMD, and reduce the response rate, among others. Moreover, some previous studies [17–22] have shown that moxibustion can improve BMD, bone strength, and hormone levels, effectively increasing the vitamin D level in serum. Moxibustion also improves bone calcium content and BMD by regulating calcium and phosphorus metabolism. Thus, the experiments’ findings are moderately convincing that moxibustion can benefit osteoporosis.

Based on the available studies, it is evident that some previous systematic reviews (SR) still exist [23]. However, no definite conclusion has been confirmed regarding the efficacy of moxibustion in treating PO [24]. Simultaneously, numerous randomized controlled trials (RCTs) have revealed that moxibustion may be applied for treating PO compared with first-line treatment, including calcium supplementation. Furthermore, the sample size of these RCTs was found to be commonly small, which none of the studies conducting sample size estimation and sequential analysis of the included studies, which could lead to bias and false-positive results. Therefore, this meta-analysis was designed to resolve the described issues and provide evidence regarding moxibustion therapy’s efficacy in managing PO.

2. Methods

This present review was registered at PROSPERO (CRD42021291310). In addition, the study was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [25], and a measurement tool to assess systematic Reviews-2 [26].

2.1. Eligibility and Exclusion Criteria

2.1.1. Eligibility Criteria

(i) Types of studies: the study included all randomized controlled parallel trials of moxibustion for PO published, regardless of the language or publication type.

(ii) Types of participants: participants with all types of PO, regardless of type, gender, age, etiology, ethnic groups, severity, and diagnosis with specific criteria, were eligible for inclusion in this review.

(iii) Types of interventions: the moxibustion approach was included in this present review as a monotherapy or complementary therapy.

(iv) Types of the control group: the control group included the conventional-based medicine group (calcium supplementation).

(v) Types of outcome measures: our primary outcome was a reduction in pain intensity (as determined by the Visual Analogue Scale, VAS). The secondary outcomes included response rate, BMD improvement of the lumbar spine, and improvement in limited mobility (as determined by Oswestry Disability Index, ODI).

2.2. Exclusion Criteria. Studies that met any of the following exclusion criteria were excluded in this present review: (1) Non-RCTs, qualitative studies, case reports, conference abstracts, expert experience, letters, comments, animal studies, and duplicated articles; (2) Incomplete research information.

2.3. Search Strategy. This review retrieved studies published from inception to December 1, 2021, from various databases, including the Chinese Biomedical Literature Database, China National Knowledge Infrastructure, Wanfang Database, VIP Database, Web of Science (1965–2021) through the Web of Knowledge, Embase (1974–2021) through Ovid, Medical Literature Analysis and Retrieval System Online (1966–2021) through PubMed, the Cochrane Central Register of Controlled Trials (The Cochrane Library, 2021, Issue 8), and Allied and Complementary Medicine Database (1985–2021) through EBSCO.

This study searched for the ongoing trials with unpublished data in the clinical trial registries, including the World Health Organization International Clinical Trials Registry Platform, National Institutes of Health clinical registry (Clinical trials.gov), and the Chinese Clinical Trial Register (ChiCTR), to minimize the risk of publication bias. Moreover, reference lists from similar published SRs/MAs were manually reviewed. The search terms used were osteoporosis, bone loss, brittle-bone disease, moxibustion, acupoint, and random trial, among others. Furthermore, the terms were connected using “and,” “or,” whereas Chinese retrieval modes were similar to English retrieval and the searching strategies of databases, as shown in Appendix 1.

2.4. Study Selection and Data Extraction. Two researchers (ZY and XL) were trained to independently extract data for this study. During the study selection, the researchers excluded duplicate studies using NoteExpress V.3.0. Subsequently, they assessed the titles/abstracts of identified studies to exclude unmatched studies according to exclusion criteria. Finally, the researchers read the full text of the studies to select those that met the inclusion criteria for this study. Accordingly, any divergences in the data obtained were solved through discussion between them.

Data extraction was accomplished by the reviewers (ZY and XL) using a standardized data extraction form that included the following information: the first author, publication year, country, sample size, allocation ratio, type of PO, age, gender, course of the disease, moxibustion group detail, control group detail, acupoint, duration of treatment,
follow-up period, and outcome. Furthermore, any disagreements were resolved by a third party (XL or LZ) and the original corresponding/first author of the study was contacted in case of missing or incomplete information in anyRCTs.

2.5. Quality Assessment. The Cochrane risk of bias tool 2.0 (ROB 2.0) [27] was used for the risk of bias. The ROB 2.0 contains five domains (the randomization process, deviation from intended interventions, missing outcomes data, outcome measurement, and selection of the reported results) of low, high, or unclear risk bias. Two researchers (ZY and XL) independently assessed the quality, whereas any disagreement was resolved by an intercessor (LZ).

2.6. Statistical Analysis. Statistical analysis of the data obtained in this study was performed using Review Manager (RevMan) Version 5.4 software. Risk ratios (RRs) with a 95% confidence interval (CI) were also calculated for dichotomous data. In addition, the mean differences with a 95% CI were calculated for continuous data. The fixed-effects model was used for data analysis when the \( p \leq 0.1 \) and \( I^2 \leq 50\% \); otherwise, the random-effects model was applied. Moreover, the fixed-effects model was conducted based on the Mantel–Haenszel method. Otherwise, the random-effects model was performed using the Der Simonian–Laired method. In this study, sensitivity analyses were also performed on the data obtained to determine the robustness of the results. Furthermore, when the included RCTs > 2, the potential publication bias of the studies was investigated using Egger’s test, and no publication bias was reported if the \( p < 0.05 \).

2.7. Trial Sequential Analysis. TSA [28, 29] was used to reduce the risk of false-positive results by repeating statistical tests and detecting the required information size (RIS) using TSA 0.9.5.10 β software (Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2016) for each outcome. This review calculated the RIS for each variable using a value of 5% for type I error and 20% for type II error (equal to 80% power). Therefore, this study displayed futility boundaries according to O’Brien-Fleming’s alpha-spending function; the difference between the two therapies demonstrated a sufficient sample size if the cumulative Z-curve exceeded the futility boundaries.

2.8. Quality of Evidence. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool [30] was used to assess the quality of evidence and categorize them as high, moderate, low, or critically low.

2.9. Assessing Reviewer Agreements. The intraclass correlation coefficient score [31] of the two researchers in this review study was 0.86.

3. Results

3.1. Study Description

3.1.1. Literature Search. This study’s searching and selecting process is shown in the PRISMA flowchart in Figure 1. Overall, 1354 potentially eligible studies were found after a comprehensive search during this review. Furthermore, 896 articles were identified after removing duplicate records for initial screening. After initial screening, 258 articles were subsequently left for review of their full text. Finally, 244 articles were excluded (14 non-RCT, 105 nonmoxibustion, and 125 noncalcium supplementations) from this review following the full text articles screening, and 14 studies [32–45] with 898 patients remained for the systematic review.

3.1.2. Study Characteristics. The primary characteristics of the 14 articles included in this SR are summarized in Table 1. All included studies were conducted in China, with sample sizes of less than 90. In addition, the allocation ratios of 12 included trials [32–45] were 1:1. Postmenopausal osteoporosis is generally considered the most common type of PO. Furthermore, the mean age of the patients was 40 to 80 years, and the proportion of females was significantly higher than that of males. Simultaneously, the mean course of the disease was 20 to 60 months.

In the intervention group, it was found that moxibustion plus calcium supplementation was the frequently used therapy, and the control groups only used calcium supplementation. The intervention duration of 8 trials (57.14%) was 90 days (3 months). However, it was evident that only two studies included follow-up (30 days). In addition, it was found that the most reported outcome was pain intensity improvement. Specific acupoints of the moxibustion therapy are presented in Table 1; Shenshu (BL23) and Mingmen (GV4) were the most frequently used acupoints, whereas the most commonly used meridian was Du Meridian.

3.2. Quality Assessment. The ROB of RCTs included in this SR was assessed according to the Cochrane ROB 2.0 tool. In addition, the ROB graphs (Figure 2) were generated using the Shiny app (https://mcguinlu.shinyapps.io/robvis/). Although all included articles were reported being randomized in the randomization process, nine RCTs were uncertain because of unclear random sequence generation. In deviation from the intended interventions, it was found that all studies had the same concerns because of the lack of explanation. Only two studies [35, 43] in this SR demonstrated reliable outcome measurement. Notably, all studies were at
a low risk of missing outcome data. Fourteen RCTs were evaluated for some concerns because of the lack of protocol/registration when selecting the reported results.

4. Results of Meta-Analysis and TSA

4.1. Reduction in Pain Intensity

4.1.1. Moxibustion Vs. CM. Overall, two trials investigated the reduction in pain intensity of moxibustion on PO compared with CM, according to the findings of this study. A random-effects model revealed no significant difference \((n = 127; \text{MD}, 1.34, 95\% \text{ CI} (-0.59; 3.27); \text{Figure 3})\) in the reduction of pain intensity with marked heterogeneity \((I^2 = 97\%, \ p < 0.00001)\). Therefore, various acupoints may result in heterogeneity. In a comparative analysis between moxibustion and CM, TSA revealed that the cumulative Z-curve uncrossed the RIS boundary (RIS = 562), indicating that the sample size was insufficient to confirm the findings of the study (Figure 4).

4.1.2. Moxibustion plus CM vs. CM. Overall, eight trials investigated the reduction in pain intensity of moxibustion plus CM on PO compared to CM. In addition, the random-effects model revealed a significant difference \((n = 494; \text{MD}, 1.84, 95\% \text{ CI} (1.37; 2.31); \text{Figure 5})\) in the reduction of pain intensity with marked heterogeneity \((I^2 = 87\%, \ p < 0.00001)\). A sensitivity analysis was conducted, which clearly demonstrated that the inclusion or exclusion of any article had no substantial impact on the MD estimate (Figure 6).

Results of the Egger's test conducted in this study revealed no significant reporting bias among RCTs for improvement in BMD \((p = 0.909 > 0.05; \text{Figure 7})\). Notably, TSA revealed that the cumulative Z-curve had crossed the RIS boundary (RIS = 76) in a comparative study between moxibustion plus CM and CM, and this indicated that the sample size was sufficient to determine whether moxibustion plus CM was superior to CM in reducing pain intensity (Figure 8).
Table 1: Main characteristics of included RCTs.

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Sample size</th>
<th>Allocation ratio</th>
<th>Type of PO</th>
<th>Sample size</th>
<th>Gender (M: F)</th>
<th>Course of the disease (Month)</th>
<th>Treatment Group</th>
<th>Control Group 1</th>
<th>Acupoints selection</th>
<th>Duration of treatment</th>
<th>Follow-up</th>
<th>Efficacy criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao et al. [32]</td>
<td>China</td>
<td>82</td>
<td>1:1</td>
<td>SOP</td>
<td>65.3 ± 1.5</td>
<td>A: 19: 22</td>
<td>A: 24–48</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Dazhu (BL11), Shenshu (BL23), Pishu (BL20), Zusanli (ST36), Zhongwan (CV12), Guanyuan (CV4)</td>
<td>90d</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Lin et al. [33]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PMOP</td>
<td>59.50 ± 5.92</td>
<td>All female</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Du Meridian, from Dazhui (GV14) to Yaoshu (GV2)</td>
<td>90d</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tian [34]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PO</td>
<td>64.21 ± 6.50</td>
<td>A: 28: 0</td>
<td>A: 22.81 ± 12.30</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Lumbosacral portion from L2 to S1, Pishu (BL20), Shenshu (BL23), Yaoyangguan (GV3), Mingmen (GV4)</td>
<td>28d</td>
<td>30d</td>
<td></td>
</tr>
<tr>
<td>Tao [35]</td>
<td>China</td>
<td>76</td>
<td>1:1</td>
<td>PO</td>
<td>69.42 ± 6.27</td>
<td>A: 22: 16</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Dazhu (BL11), Shenshu (GV12), Mingmen (GV4), Shenshu (BL23), Pishu (BL20), Zhongwan (CV12), Shenque (CV8), Zusanli (ST36), Guanyuan (CV4), Xuanzhong (GB39), Sanyinjiao (SP6), Yinlingguan (SP9), Taixi (KI3)</td>
<td>84d</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gu [36]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PMO</td>
<td>60.12 ± 3.67</td>
<td>All female</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Shenshu (BL23)</td>
<td>140d</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu et al. [37]</td>
<td>China</td>
<td>63</td>
<td>32:31</td>
<td>PMO</td>
<td>65.16 ± 6.82</td>
<td>All female</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Pishu (BL20), Shenshu (BL23), Yaoyangguan (GV3), Mingmen (GV4)</td>
<td>28d</td>
<td>30d</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wu [38]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PMO</td>
<td>45–65</td>
<td>All female</td>
<td>&gt;12</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Pishu (BL20), Shenshu (BL23)</td>
<td>90d</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Yang et al. [39]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PO</td>
<td>45–80</td>
<td>A: 11: 19</td>
<td>A: 24–84</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Du Meridian, from Dazhui (GV14) to Yaoshu (GV2)</td>
<td>84d</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>Lin et al. [40]</td>
<td>China</td>
<td>70</td>
<td>1:1</td>
<td>PMO</td>
<td>45–75</td>
<td>All female</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Du Meridian, from Dazhui (GV14) to Yaoshu (GV2)</td>
<td>90d</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ouyang and Xu</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PMO</td>
<td>62.45 ± 7.68</td>
<td>All female</td>
<td>Mox + CM</td>
<td>CM (calcium supplementation)</td>
<td>Pishu (BL20), Weishu (BL21), Shenshu (BL23), Mingmen (GV4), Yaoyangguan (GV3), Zhiyang (GV9)</td>
<td>90d</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Sample size</td>
<td>Allocation ratio</td>
<td>Type of PO</td>
<td>Age (Year)</td>
<td>Gender (M: F)</td>
<td>Course of the disease (Month)</td>
<td>(A) Treatment Group</td>
<td>(B) Control Group I</td>
<td>Acupoints selection</td>
<td>Duration of treatment</td>
<td>Follow-up</td>
<td>Efficacy criteria</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>-------------</td>
<td>------------------</td>
<td>------------</td>
<td>------------</td>
<td>--------------</td>
<td>-------------------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>---------------------------------------------</td>
<td>----------------------</td>
<td>-----------</td>
<td>------------------</td>
</tr>
<tr>
<td>Ouyang [42]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PMO</td>
<td>62.29 ± 7.18 A: Allfemale</td>
<td>60</td>
<td>Mox + CM</td>
<td>Dazhu (BL11), Geshu (BL17), Ganshu (BL18), Shenshu (BL23), Pishu (BL20), Mingmen (GV4), Zusanli (ST36), Yanglingquan (GB34), Taixi (KI3), Guanyuanshu (BL26)</td>
<td>90d</td>
<td>—</td>
<td>1. Response rate 2. BMD 3. VAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ouyang et al. [43]</td>
<td>China</td>
<td>60</td>
<td>1:1</td>
<td>PO</td>
<td>63.25 ± 10.14 A: 12: 18 B: 13: 17</td>
<td>—</td>
<td>Mox + CM</td>
<td>Dazhu (BL11), Geshu (BL17), Ganshu (BL18), Shenshu (BL23), Pishu (BL20), Mingmen (GV4), Zusanli (ST36), Yanglingquan (GB34), Taixi (KI3), Guanyuanshu (BL26)</td>
<td>90d</td>
<td>—</td>
<td>1. VAS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu and Jin [45]</td>
<td>China</td>
<td>67</td>
<td>36: 31</td>
<td>PO</td>
<td>87.96 ± 44.04 A: 8: 23 B: 9: 27 50–82</td>
<td>90d</td>
<td>Mox</td>
<td>CM (calcium supplementation)</td>
<td>Shenque (CV8), Guanyuan (CV4), Qihai (CV6), Mingmen (GV4), Shenshu (BL23), Pishu (BL20)</td>
<td>—</td>
<td>1. Response rate 2. VAS</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: SO: senile osteoporosis; PMO: postmenopausal osteoporosis; PO: primary osteoporosis; Mox: moxibustion; CM: conventional medicine; d: day; VAS: visual analogue scale; BMD: bone mineral density; ODI: Oswestry disability index.
4.2. Response Rate

4.2.1. Moxibustion Vs. CM. Overall, three trials investigated the response rate of moxibustion on PO compared with CM. A fixed-effect model in this study revealed a significant difference ($n = 203$; RR, 1.32, 95% CI (1.14; 1.53; Figure 9) in the response rate with low heterogeneity ($I^2 = 22\%$, $p = 0.28$). In addition, Egger's test results in this review showed no significant reporting bias among RCTs for response rate ($p = 0.679 > 0.05$; Figure 10). A comparative analysis between moxibustion and CM noted that TSA revealed an ignored boundary RIS because of insufficient information used.

4.2.2. Moxibustion plus CM vs. CM. Overall, four trials investigated the response rate of moxibustion plus CM on PO compared with CM. A fixed-effect model revealed significant difference ($n = 256$; RR, 1.38, 95% CI (1.20; 1.59); Figure 11) in the response rate with low heterogeneity ($I^2 = 0\%$, $p = 0.69$). In addition, Egger's test results in this review showed significant reporting bias among RCTs for response rate ($p = 0.036 < 0.05$; Figure 12). A comparative analysis between moxibustion plus CM and CM noted that TSA revealed an ignored boundary RIS because of insufficient information used.

4.3. Improvement in BMD

4.3.1. Moxibustion vs. CM. Overall, four trials investigated the improvement in BMD of moxibustion on PO compared with CM. A fixed-effect model indicated no significant difference ($n = 256$; MD, 0.00, 95% CI (0.00; 0.01; Figure 13) in BMD improvement with low heterogeneity ($I^2 = 0\%$, $p = 0.46$). Egger’s test showed no significant reporting bias among RCTs for improvement in BMD ($p = 0.140 > 0.05$; Figure 14). In a comparative analysis between moxibustion and CM, TSA revealed that boundary RIS was ignored because of insufficient information used.

4.3.2. Moxibustion plus CM vs. CM. Overall, three trials were conducted to compare the improvement in BMD of moxibustion plus CM on PO to CM. A fixed-effect model revealed no significant difference ($n = 199$; MD, 0.02, 95% CI ($-0.00; 0.03$); Figure 15) in BMD improvement with low heterogeneity ($I^2 = 37\%$, $p = 0.20$). Furthermore, the results of Egger’s test showed no significant reporting bias among RCTs for improvement in BMD ($p = 0.056 > 0.05$) (Figure 16). In a comparative analysis between moxibustion plus CM and CM, TSA revealed that boundary RIS was ignored because of insufficient information used.

4.4. Improvement in ODI. Overall, two trials investigated the improvement in ODI of moxibustion plus CM on PO compared with CM. The results of a random-effects model showed a significant difference ($n = 118$; MD, 5.99, 95% CI (1.92; 10.07); Figure 17) in ODI improvement with marked heterogeneity ($I^2 = 70\%$, $p = 0.07$). Therefore, it was evident that various acupoints may result in heterogeneity. In a comparative analysis between moxibustion plus CM and CM, TSA revealed that the cumulative Z-curve uncrossed the RIS boundary (RIS = 125). Therefore, this indicated that the sample size was insufficient to determine whether moxibustion plus CM was superior to CM regarding ODI improvement (Figure 18).

4.5. Safety. Four RCTs reported the safety of the intervention. One study [33] mentioned that moxibustion caused blisters, which did not affect the overall process after proper treatment; another study [44] stated that calcium supplementation caused mild nausea and vomiting; two other studies [34, 45] clearly demonstrated that no adverse effects occurred during the treatment process. The other 10 RCTs did not clearly indicate moxibustion’s side effects or safety.

4.6. Quality of Evidence. The GRADE approach was used to evaluate the quality of included evidences of the RCTs (Table 2). Four outcomes were included: reduction in pain intensity, response rate, improvement in BMD, and improvement in ODI. Overall, the evidence was of low or critically low quality. However, the poor methodological quality and insufficient sample size were the primary reasons for its degradation.

5. Discussion

PO is one of the defining health issues for patients, families, and society of an aging population [1]. Currently, calcium supplementation is the most frequent and recognized antiosteoporosis medicine for treating PO because it improves bone metabolism and BMD [37]. In China, moxibustion has been widely used for several chronic musculoskeletal disorders, including PO and knee osteoarthritis, among others. However, previous studies have generally demonstrated no definite conclusion on the efficacy of moxibustion for PO.

Recently, several clinical RCTs have evaluated the effects of moxibustion on PO, and it has been demonstrated that moxibustion may increase patient benefit against PO. In addition, numerous experiments have shown that moxibustion treatment is associated with increased bone formation markers [41], decreased bone resorption markers and increased hormone levels [32] in patients with. Qian and Fan [46] demonstrated that moxibustion treatment could improve the messenger ribonucleic acid (mRNA) level of osteoprogenitor (OPG), reduce the mRNA level of the receptor activator of nuclear factor-κB ligand, promote the combination of OPG and receptor activator for nuclear factor-κB, block signal transmission of osteoclast chain reactions, and inhibit bone resorption. Yao et al. [47] found that moxibustion in specific acupoints in osteoporosis model rats can improve the activity of bone marrow mesenchymal stem cells (BMMSCS), activate the Wnt/β-catenin signaling pathway, and promote BMMSCS differentiation into osteoblasts. Therefore, based on the
above research evidences, this study was conducted and aimed to provide evidence for the efficacy of moxibustion on PO.

In the 14 RCTs included in this study, moxibustion or moxibustion plus CM (calcium supplementation) was found to be superior to CM. This current review involved

---

<table>
<thead>
<tr>
<th>Study</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao 2021</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lin 2020</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Tian 2019</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Tao 2019</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Gu 2019</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Xu 2018</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Wu 2017</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Yang 2014</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Lin 2013</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Ouyang 2013</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Ouyang 2012a</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Ouyang 2012b</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Li 2011</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>Xu 2010</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

Domains:
D1: Bias arising from the randomization process.
D2: Bias due to deviations from intended intervention.
D3: Bias due to missing outcome data.
D4: Bias in measurement of the outcome.
D5: Bias in selection of the reported result.

Judgement
Some concerns
Low

---

**Figure 2:** (a) Risk of bias graph. (b) Risk of bias summary.
Study or Subgroup | Moxibustion Mean | SD | Total | CM Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI
---|---|---|---|---|---|---|---|---|---|---
Wu 2017 | 1.31 | 1.23 | 30 | 0.98 | 1.14 | 30 | 48.9 | 0.33 [−0.27, 0.93] | 0.33 [−0.27, 0.93]
Xu 2010 | 4.64 | 0.48 | 36 | 2.34 | 0.31 | 31 | 51.1 | 2.30 [2.11, 2.49] | 2.30 [2.11, 2.49]
Total (95% CI) | 66 | 61 | 100.0 | 1.34 [−0.59, 3.27] | 1.34 [−0.59, 3.27]

Heterogeneity: tau² = 1.89; chi² = 37.59, df = 1 (P< 0.00001); I² = 97%
Test for overall effect: Z = 1.36 (P = 0.17)

Figure 3: Meta-analysis forest plot of reduction in pain intensity of moxibustion vs. CM.

Figure 4: Trial sequential analysis on moxibustion vs. CM of reduction in pain intensity.

Study or Subgroup | Moxibustion+CM Mean | SD | Total | CM Mean | SD | Total | Weight (%) | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI
---|---|---|---|---|---|---|---|---|---|---
Tao 2021 | 4.78 | 0.46 | 41 | 3.2 | 0.59 | 41 | 15.4 | 1.58 [1.35, 1.81] | 1.58 [1.35, 1.81]
Lin 2020 | 4.12 | 1.33 | 28 | 1.06 | 1.25 | 29 | 12.0 | 3.06 [2.39, 3.73] | 3.06 [2.39, 3.73]
Tian 2019 | 2.29 | 1.54 | 28 | 1.07 | 1.97 | 27 | 9.7 | 1.22 [0.28, 2.16] | 1.22 [0.28, 2.16]
Xu 2018 | 2.2 | 1.17 | 31 | 1.32 | 1.4 | 29 | 12.1 | 0.88 [0.22, 1.54] | 0.88 [0.22, 1.54]
Yang 2014 | 3.84 | 0.48 | 30 | 1.81 | 0.42 | 30 | 15.4 | 2.03 [1.80, 2.26] | 2.03 [1.80, 2.26]
Lin 2013 | 4.13 | 1.37 | 32 | 2.64 | 1.36 | 31 | 12.0 | 1.49 [0.82, 2.16] | 1.49 [0.82, 2.16]
Ouyang 2012a | 1.14 | 1.23 | 29 | 0.11 | 1.2 | 28 | 12.4 | 1.03 [0.40, 1.66] | 1.03 [0.40, 1.66]
Ouyang 2012b | 3.7 | 1.13 | 30 | 0.2 | 1.85 | 30 | 11.1 | 3.50 [2.72, 4.28] | 3.50 [2.72, 4.28]
Total (95% CI) | 249 | 245 | 100.0 | 1.84 [1.37, 2.31] | 1.84 [1.37, 2.31]

Heterogeneity: tau² = 0.35; chi² = 55.03, df = 7 (P < 0.00001); I² = 87%
Test for overall effect: Z = 7.74 (P < 0.00001)

Figure 5: Meta-analysis forest plot of reduction in pain intensity of moxibustion plus CM vs. CM.

Meta-analysis estimates, given named study is omitted

Figure 6: Sensitivity analysis of reduction in pain intensity of moxibustion plus CM vs. CM.
four outcomes, including a reduction in pain intensity, response rate, improvement in BMD, and improvement in ODI, and the following findings were obtained: first, it was evident that moxibustion showed no statistically significant difference in the reduction of pain intensity in patients with PO as compared with that of CM. The quality of evidence was classified as critically low. Furthermore, the reduction of pain intensity by moxibustion plus CM showed statistically significant differences as compared with that of CM, and the quality of evidence was classified.
as low. Second, moxibustion/moxibustion plus CM demonstrated significant differences in response rate as compared with the rate shown by CM, and the evidence quality was ranked as low to critically low. Third, when moxibustion plus CM was compared with CM alone, the results showed a significant improvement in ODI, and the evidence level was classified as critically low. Fourth, it was evident that no statistical differences were reported in increasing BMD between treatments with moxibustion/moxibustion plus CM, as compared with CM only, and the evidence obtained was ranked as low quality. Simultaneously, only one study reported the adverse events caused by moxibustion. To our knowledge, the burning of moxa does not directly contact with the skin of patients, and the treatment process is safe under the close attention of doctors.

To the best of our best knowledge, this study is the first trial sequential meta-analysis to certify moxibustion therapy for reduction in pain intensity, response rate, improvement in BMD, and improvement in ODI in patients with PO. Therefore, this review’s findings provide credible evidence to assist in making clinical decisions on the management of PO. Furthermore, a sequential trial analysis was conducted to measure statistical reliability and estimate the optimum sample size of included RCTs. In addition, the GRADE approach was used to evaluate the quality of evidence derived from the included RCTs.

However, this review had some limitations. First, the primary limitation was the low quality of the evidence. Second, the methodological quality of the included studies was poor, which could impact the findings’ reliability and reduce efficiency. Third, variability in study design, bias risk, and other factors may cause methodological heterogeneity. Fourth, moxibustion differs in terms of acupoints, method, and frequency, leading to heterogeneity. Fifth, all RCTs published in English/Chinese were implemented in China, which may have resulted in region bias. Sixth, the incidence of fracture, and serum factors (inflammatory indicators, bone metabolism parameters, and other factors) as endpoint outcomes of PO, were ignored in the included studies. Finally, the long-term follow-up evaluation is lacking in this review, yet PO is a chronic disease.

This review identifies some suggestions for further research. First, the overall reliability of the research conclusion is not high because of the poor quality of evidence. Therefore, it is suggested that future research should discreetly and strictly strive to perfect its designs according to the latest edition of the Cochrane Handbook for Systematic Reviews, Consolidated Standards of Reporting Trials [48],
and Standards for Reporting Interventions in Clinical Trials of moxibustion [49].

Simultaneously, clinical heterogeneity existed in this review due to factors, including acupoints, and treatment duration, among others. However, this study also clearly had no certain relationships; thus, the relationship between moxibustion factors and efficacy is an important point for future research. In addition, this study aimed to investigate the short-term efficacy of moxibustion; however, the long-term efficacy of moxibustion for PO is yet to be investigated. Therefore, future research should focus on a long-term follow-up period to evaluate the long-term effects of the treatment. Moreover, underlying mechanisms of moxibustion against PO should further be investigated. Finally,
<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Moxibustion + CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao 2021</td>
<td>0.17</td>
<td>0.33</td>
<td>41</td>
<td>0.05</td>
<td>0.3</td>
<td>41</td>
<td>2.0</td>
<td>0.12 [-0.02, 0.26]</td>
<td></td>
</tr>
<tr>
<td>Yang 2014</td>
<td>0.09</td>
<td>0.13</td>
<td>30</td>
<td>0.05</td>
<td>0.1</td>
<td>30</td>
<td>10.9</td>
<td>0.04 [-0.02, 0.10]</td>
<td></td>
</tr>
<tr>
<td>Ouyang 2012a</td>
<td>0.01</td>
<td>0.04</td>
<td>29</td>
<td>0</td>
<td>0.04</td>
<td>28</td>
<td>87.1</td>
<td>0.01 [-0.01, 0.03]</td>
<td></td>
</tr>
<tr>
<td>Total (95%CI)</td>
<td></td>
<td></td>
<td></td>
<td>100.0</td>
<td></td>
<td></td>
<td>0.02 [-0.00, 0.03]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 3.19$, df = 2 ($P = 0.20$); $I^2 = 37$
Test for overall effect: $Z = 1.57$ ($P = 0.12$)

Favours [CM] Favours [Moxibustion+CM]

Figure 15: Meta-analysis forest plot of improvement in BMD of moxibustion plus CM vs. CM.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Moxibustion + CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tian 2019</td>
<td>7.54</td>
<td>4.32</td>
<td>28</td>
<td>3.49</td>
<td>6.05</td>
<td>27</td>
<td>53.4</td>
<td>4.05 [1.26, 6.84]</td>
<td></td>
</tr>
<tr>
<td>Lin 2013</td>
<td>27.46</td>
<td>6.92</td>
<td>32</td>
<td>19.24</td>
<td>7.28</td>
<td>31</td>
<td>46.6</td>
<td>8.22 [4.71, 11.73]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>60</td>
<td>58</td>
<td>100.0</td>
<td>5.99 [1.92, 10.07]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\hat{\tau}^2 = 6.08$; $\chi^2 = 3.33$, df = 1 ($P = 0.08$); $I^2 = 70$
Test for overall effect: $Z = 2.88$ ($P = 0.004$)

Favours [Moxibustion+CM] Favours [CM]

Figure 16: Egger’s test plot on moxibustion plus CM vs. CM of improvement in BMD.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Moxibustion + CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tian 2019</td>
<td>7.54</td>
<td>4.32</td>
<td>28</td>
<td>3.49</td>
<td>6.05</td>
<td>27</td>
<td>53.4</td>
<td>4.05 [1.26, 6.84]</td>
<td></td>
</tr>
<tr>
<td>Lin 2013</td>
<td>27.46</td>
<td>6.92</td>
<td>32</td>
<td>19.24</td>
<td>7.28</td>
<td>31</td>
<td>46.6</td>
<td>8.22 [4.71, 11.73]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>60</td>
<td>58</td>
<td>100.0</td>
<td>5.99 [1.92, 10.07]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\hat{\tau}^2 = 6.08$; $\chi^2 = 3.33$, df = 1 ($P = 0.08$); $I^2 = 70$
Test for overall effect: $Z = 2.88$ ($P = 0.004$)

Favours [Moxibustion+CM] Favours [CM]

Figure 17: Meta-analysis forest plot of improvement in ODI of moxibustion plus CM vs. CM.

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Moxibustion + CM Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight (%)</th>
<th>Mean Difference IV, Random, 95% CI</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tian 2019</td>
<td>7.54</td>
<td>4.32</td>
<td>28</td>
<td>3.49</td>
<td>6.05</td>
<td>27</td>
<td>53.4</td>
<td>4.05 [1.26, 6.84]</td>
<td></td>
</tr>
<tr>
<td>Lin 2013</td>
<td>27.46</td>
<td>6.92</td>
<td>32</td>
<td>19.24</td>
<td>7.28</td>
<td>31</td>
<td>46.6</td>
<td>8.22 [4.71, 11.73]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>60</td>
<td>58</td>
<td>100.0</td>
<td>5.99 [1.92, 10.07]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\hat{\tau}^2 = 6.08$; $\chi^2 = 3.33$, df = 1 ($P = 0.08$); $I^2 = 70$
Test for overall effect: $Z = 2.88$ ($P = 0.004$)

Favours [Moxibustion+CM] Favours [CM]

Figure 18: Trial sequential analysis on moxibustion plus CM vs. CM of improvement in ODI.
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Included RCTs (patients)</th>
<th>Relative effect (95% CI)</th>
<th>Risk of bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Publication bias</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reduction in pain intensity</strong></td>
<td>Mox vs. CM</td>
<td>2 (127) MD -1.34 (-3.27 to 0.59)</td>
<td>-1(\text{①}) -1(\text{②}) 0 -1(\text{③}) 0</td>
<td>Low</td>
<td>Critically low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mox plus CM vs. CM</td>
<td>8 (494) MD -1.84 (-2.31 to -1.37)</td>
<td>-1(\text{①}) -1(\text{②}) 0 0 0</td>
<td>Low</td>
<td>Critically low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Response rate</strong></td>
<td>Mox vs. CM</td>
<td>3 (203) RR 1.32 (1.14 to 1.53)</td>
<td>-1(\text{①}) 0 0 -1(\text{③}) 0</td>
<td>Low</td>
<td>Low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mox plus CM vs. CM</td>
<td>4 (256) RR 1.38 (1.20 to 1.59)</td>
<td>-1(\text{①}) 0 0 -1(\text{③}) -1(\text{④})</td>
<td>Low</td>
<td>Critically low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Improvement in BMD</strong></td>
<td>Mox vs. CM</td>
<td>4 (256) MD 0.00 (0.00 to 0.01)</td>
<td>-1(\text{①}) 0 0 -1(\text{③}) 0</td>
<td>Low</td>
<td>Low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mox plus CM vs. CM</td>
<td>3 (199) MD 0.02 (0.00 to 0.03)</td>
<td>-1(\text{①}) 0 0 -1(\text{③}) 0</td>
<td>Low</td>
<td>Low</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Improvement in ODI</strong></td>
<td>Mox plus CM vs. CM</td>
<td>2 (118) MD -5.99 (-10.07 to -1.92)</td>
<td>-1(\text{①}) -1(\text{②}) 0 -1(\text{③}) 0</td>
<td>Critical low</td>
<td>Low</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: Mox: moxibustion; CM: conventional medicine; BMD: bone mineral density; ODI: Oswestry disability index; MD: mean difference; RR: relative risk; \(\text{①}\): Poor methodological quality. \(\text{②}\): The size and direction of the effect size, the overlap of the confidence interval is small, the p value of the heterogeneity test is small, and the combined results of I2 value are large. \(\text{③}\): Insufficient sample size. \(\text{④}\): Significant reporting bias.
fracture incidence is obviously a vital endpoint outcome of PO, and future trials should pay more attention to fracture incidence.

6. Conclusion
In conclusion, this study demonstrated that moxibustion can provide clinical benefits for PO conditions and had a significant response rate in PO management. However, due to evidence of poor quality, further research is warranted with additional well-designed and high-quality large-scale RCTs to confirm the findings of this study.

Data Availability
The data would be made available upon request.

Ethical Approval
This work did not require an ethical approval as it does not involve any human or animal experiment.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
Xiang Li, Zihan Yin, and Xiao Li contributed equally to this work. Xiang Li, Wenchuan Qi, and Fanrong Liang conceived this study. Xiang Li, Zihan Yin, and Xiao Li developed and implemented the systematic review, under the supervision of Wenchuan Qi. Zihan Yin and Bingzun Yin provided the statistical analysis plan for the study and performed data analysis. Zihan Yin and Xiao Li performed study search, screening, and extraction of data, whereas Xiang Li reviewed the work. Xiang Li wrote the first draft of the current review, with Zihan Yin, Xiao Li and Yixiang Liu provided input to the final draft. All authors read and approved the final manuscript. Editage (https://www.editage.cn) helped us for English language editing.

Acknowledgments
This work was financially supported by the National Natural Science Foundation of China (nos. 82105027, 81590951, 82004486, 81722050, and 81973961).

Supplementary Materials
Appendix 1. Search strategies of each database. (Supplementary Materials)

References
Evidence-Based Complementary and Alternative Medicine


